CELL INTELLIGENCE · 肿瘤细胞治疗研究

CAR 疗法在肿瘤与自身免疫领域的演进：机制见解与治疗创新

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

Lisaftoclax 联合伊沙佐米和地塞米松在 CAR-T 后用于不适合移植的复发/难治性超高危多发性骨髓瘤维持治疗：两例病例报告及文献综述

Lisaftoclax combined with ixazomib and dexamethasone after CAR-T for maintenance therapy in transplant-ineligible relapsed/refractory ultra-high-risk

CAR-T 细胞疗法在实体瘤中的挑战与局限：为何获批仅限于血液系统恶性肿瘤？

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

肿瘤 CAR-T 细胞治疗：当前挑战与未来方向

CAR-T cell therapy for cancer: current challenges and future directions.

CAR-T 细胞治疗实体瘤的挑战与进展

The challenges and progress of CAR-T cell therapy in the treatment of solid tumors.

用于 CAR-T 细胞治疗的一种新型分选细胞——分离 CD14(-)CD127(+) T 细胞用于 CAR-T 细胞制备

A new sort of cells for chimeric antigen receptor T-cell therapies-isolating CD14(-)CD127(+) T cells for chimeric antigen receptor T-cell manufacture.

我们开发了一种新的两步分离方法，用于从 PBMC 中富集 CD14⁻CD127⁺ T 细胞。

释放 CAR-T 细胞治疗的潜力：血液肿瘤与实体瘤治疗中的进展、挑战与未来方向

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.